Cardiff Oncology, Inc. (CRDF) Financial Ratios
21 years of historical data (2005–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
2.34
+19% vs avg
5yr avg: 1.96
30Y Low0.6·High88.2
ROE
↓
-71.5%
↑-55% vs avg
5yr avg: -46.1%
30Y Low-198%·High-21%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CRDF Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Cardiff Oncology, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $109M | $188M | $207M | $66M | $61M | $235M | $376M | $7M | $7M | $11M | $64M |
| Enterprise Value | $92M | $171M | $157M | $47M | $47M | $226M | $245M | $-1061307 | $-4043028 | $4M | $42M |
| P/E Ratio → | -2.30 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 183.32 | 316.73 | 302.78 | 135.50 | 158.13 | 653.40 | 1026.07 | 30.28 | 19.60 | 21.29 | 166.90 |
| P/B Ratio | 2.34 | 4.14 | 2.49 | 0.95 | 0.57 | 1.67 | 2.93 | 1.01 | 0.73 | 1.65 | 3.22 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CRDF EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 288.68 | 229.65 | 95.52 | 122.82 | 628.82 | 670.57 | -4.34 | -10.70 | 7.64 | 110.85 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
CRDF Profitability
Margins and return-on-capital ratios measuring operating efficiency
Cardiff Oncology, Inc. earns an operating margin of -8256.3%. Operating margins have expanded from -9305.7% to -8256.3% over the past 3 years, signaling improving operational efficiency. A negative ROE of -71.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -57.9% | -258.6% | -354.1% |
| Operating Margin | -8256.3% | -8256.3% | -7123.1% | -9305.7% | -10337.3% | -8037.6% | -5214.8% | -6817.8% | -4511.4% | -5068.5% | -10536.7% |
| Net Profit Margin | -7732.0% | -7732.0% | -6651.7% | -8492.0% | -10026.9% | -7880.5% | -5275.1% | -6709.7% | -4354.8% | -4932.1% | -10289.8% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -71.5% | -71.5% | -59.5% | -47.1% | -31.4% | -21.1% | -28.5% | -188.7% | -198.4% | -189.6% | -114.5% |
| ROA | -57.6% | -57.6% | -50.8% | -41.9% | -29.1% | -19.9% | -26.1% | -120.4% | -124.4% | -88.6% | -67.9% |
| ROIC | -118.9% | -118.9% | -87.7% | -47.7% | -26.7% | -33.4% | — | — | — | — | — |
| ROCE | -75.8% | -75.8% | -62.8% | -50.6% | -31.7% | -21.2% | -27.9% | -171.0% | -174.5% | -115.1% | -80.8% |
CRDF Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $17M exceeds total debt of $832000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 | 0.01 | 0.24 | — | 0.20 | 0.84 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.37 | -0.60 | -0.28 | -0.13 | -0.06 | -1.02 | -1.16 | -1.14 | -1.06 | -1.08 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -9652.50 | — | -646.85 | -23.09 | -27.28 |
Net cash position: cash ($17M) exceeds total debt ($832000)
CRDF Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Cardiff Oncology, Inc.'s current ratio of 3.67x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 7.41x to 3.67x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.67 | 3.67 | 7.08 | 7.41 | 14.25 | 22.28 | 21.79 | 2.37 | 4.31 | 2.40 | 5.00 |
| Quick Ratio | 3.67 | 3.67 | 7.08 | 7.41 | 14.25 | 22.28 | 21.79 | 2.37 | 4.31 | 2.40 | 5.00 |
| Cash Ratio | 3.56 | 3.56 | 6.83 | 7.17 | 13.48 | 21.47 | 21.41 | 2.13 | 3.86 | 2.08 | 4.86 |
| Asset Turnover | — | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 | 0.04 | 0.01 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 112.02 | 413.10 | 215.41 | 729.05 | 543.94 | 319.13 | 303.60 | 161.99 | 55.72 | 96.24 |
CRDF Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Cardiff Oncology, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | 0.7% | 0.0% | — | 100.0% | 100.0% | 100.0% | 38.1% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.7% | 0.0% | 0.0% | 100.0% | 100.0% | 100.0% | 38.1% |
| Shares Outstanding | — | $67M | $48M | $45M | $44M | $39M | $21M | $6M | $2M | $481665 | $420568 |
Peer Comparison
Compare CRDF with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CRDFYou | $109M | -2.3 | — | — | 100.0% | -8256.3% | -71.5% | -118.9% | — |
 TGTX | $7B | 17.3 | 61.0 | — | 83.7% | 20.0% | 102.8% | 16.4% | 2.1 |
 MGNX | $255M | -3.4 | — | — | 71.1% | -48.7% | -86.9% | -144.1% | — |
 NKTR | $1B | -6.1 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 IMVT | $7B | -11.9 | — | — | — | — | -64.8% | — | — |
 KPTI | $77M | -0.5 | — | — | 95.9% | -62.1% | — | — | — |
 AGIO | $2B | -4.0 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 AGEN | $141M | -997.1 | — | — | 29.6% | -18.0% | — | — | — |
 FATE | $230M | -1.7 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 PRME | $509M | -2.1 | — | — | -58.1% | -4498.1% | -146.8% | -168.3% | — |
 RVMD | $32B | -25.1 | — | — | — | — | -58.1% | -54.3% | — |
| Healthcare Median | — | 23.1 | 14.4 | 19.0 | 64.0% | -4.2% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 18 years · Updated daily
What if you invested $1,000 in CRDF 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in CRDF be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs CRDF Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCRDF vs TGTX — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs TG Therapeutics, Inc..
Compare NowCRDF — Frequently Asked Questions
Quick answers to the most common questions about buying CRDF stock.
What is Cardiff Oncology, Inc.'s P/E ratio?
Cardiff Oncology, Inc.'s current P/E ratio is -2.3x. This places it at the 50th percentile of its historical range.
What is Cardiff Oncology, Inc.'s ROE?
Cardiff Oncology, Inc.'s return on equity (ROE) is -71.5%. The historical average is -94.1%.
Is CRDF stock overvalued?
Based on historical data, Cardiff Oncology, Inc. is trading at a P/E of -2.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Cardiff Oncology, Inc.'s profit margins?
Cardiff Oncology, Inc. has 100.0% gross margin and -8256.3% operating margin.